Zydus Cadila receives final approval from USFDA for Apremilast Tablets

Zydus Cadila's U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received final approval from the USFDA to market Apremilast Tablets in the strengths of 10 mg, 20 mg, 30 mg (US RLD: Otezla® Tablets). Zydus' Apremilast Tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 323 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Ltd. was last trading in BSE at Rs. 566.9 as compared to the previous close of Rs. 561.2. The total number of shares traded during the day was 159994 in over 4538 trades.

The stock hit an intraday high of Rs. 570.5 and intraday low of 560.7. The net turnover during the day was Rs. 90740377.

Source : Equity Bulls

Keywords